諾誠健華(09969.HK)中期總收益同比增加74.3%至7.3億元
格隆匯8月19日丨諾誠健華(09969.HK)公告,截至2025年6月30日止6個月中期業績,總收益同比增加74.3%至人民幣7.3億元,主要是由於奧布替尼銷量增長強勁及來自Prolium的許可收益。奧布替尼的收益由截至2024年6月30日止6個月的人民幣4.17億元增加52.8%至截至2025年6月30日止6個月的人民幣6.37億元,是由於覆蓋範圍拓寬及治療患者增加所致。
期內虧損由截至2024年6月30日止6個月的人民幣2.68億元減少86.7%至截至2025年6月30日止6個月的人民幣3560萬元。現金及相關賬戶結餘於2025年6月30日約爲人民幣77億元。穩健的現金狀況,使公司可靈活地加快臨牀開發,並投資具有競爭力的產品線。
於2025年上半年,公司在推進產品線方面取得重大進展,實現多個重要的里程碑。奧布替尼獲準用於治療一線慢性淋巴細胞白血病╱小淋巴細胞淋巴瘤("CLL/SLL"),坦昔妥單抗加來那度胺聯合療法獲準用於治療不符合自體幹細胞移植("ASCT")條件的成年復發或難治性DLBCL("復發難治DLBCL")患者,公司的BCL-2抑制劑ICP-248(mesutoclax)進入兩項註冊性臨牀研究,公司專有的ADC平臺亦取得重大突破,首次提交IND並獲得臨牀試驗批準。
基於此研發勢頭,公司通過戰略合作進一步擴大全球佈局,在2025年1月與Prolium達成合作探索CD3×CD20雙特異性抗體的全球潛力。公司仍致力於推動全球合作夥伴關係,以加強創新、最大化公司產品線的價值,並支持長期發展。
商業化執行依然強勁,奧布替尼的市場滲透率提高以及收益大幅增長,突顯公司將科學創新轉化爲可持續業務表現的能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.